Free Trial

Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals logo
GBX 1,855
-47.00 (-2.47%)
(As of 10/31/2024 ET)

HIK vs. HCM, INDV, AMYT, AGY, APH, ANCR, BXP, DNL, EAH, and STX

Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Animalcare Group (ANCR), Beximco Pharmaceuticals (BXP), Diurnal Group (DNL), ECO Animal Health Group (EAH), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Hikma Pharmaceuticals vs.

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.02B1.36£285M£0.652,853.85
HUTCHMED£610.81M3.97-£41.97M-£0.04-7,100.00

In the previous week, Hikma Pharmaceuticals and Hikma Pharmaceuticals both had 1 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.43 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hikma Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HUTCHMED
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Hikma Pharmaceuticals received 604 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.55% of users gave Hikma Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Hikma PharmaceuticalsOutperform Votes
800
70.55%
Underperform Votes
334
29.45%
HUTCHMEDOutperform Votes
196
78.40%
Underperform Votes
54
21.60%

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.88% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals9.45% 12.88% 9.40%
HUTCHMED -6.87%-5.44%-5.90%

42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 39.0% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,325, indicating a potential upside of 25.20%. Given Hikma Pharmaceuticals' higher probable upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Hikma Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Summary

Hikma Pharmaceuticals beats HUTCHMED on 12 of the 16 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIK vs. The Competition

MetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£4.12B£1.16B£5.36B£1.41B
Dividend Yield3.25%3.13%5.22%11.97%
P/E Ratio2,856.92107.76131.931,578.56
Price / Sales1.363,379.921,440.15209,401.64
Price / Cash8.3410.0839.0633.55
Price / Book1.803.164.742.73
Net Income£285M£141.31M£115.43M£156.08M
7 Day Performance-5.14%-0.57%-0.86%4.09%
1 Month Performance-2.93%-1.15%3.61%2.72%
1 Year Performance-2.45%96.97%38.90%24.59%

Hikma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
2.7565 of 5 stars
GBX 1,855
-2.5%
GBX 2,325
+25.3%
-0.6%£4.12B£3.02B2,856.929,100
HCM
HUTCHMED
N/AGBX 323
+2.9%
N/A-10.7%£2.76B£610.81M-8,075.001,760Gap Up
High Trading Volume
INDV
Indivior
2.7789 of 5 stars
GBX 699
+1.2%
GBX 1,500
+114.6%
-54.9%£898.84M£1.15B-873.751,000Gap Down
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
AGY
Allergy Therapeutics
N/AGBX 5.30
+6.0%
N/A+299.4%£252.81M£53.26M-88.33612
APH
Alliance Pharma
2.5988 of 5 stars
GBX 45.20
+0.4%
GBX 60
+32.7%
+13.4%£244.34M£183.15M-753.3391,000Gap Up
ANCR
Animalcare Group
N/AGBX 229
-0.4%
N/A+36.5%£138.25M£76.10M2,862.50220
BXP
Beximco Pharmaceuticals
N/AGBX 29
-1.7%
N/A-22.7%£129.37M£43.08B362.505,500
DNL
Diurnal Group
N/AGBX 27.30
flat
N/AN/A£46.33M£4.68M-3.2133
EAH
ECO Animal Health Group
N/AGBX 66
+4.8%
N/A-29.5%£44.71M£89.42M3,300.00234
STX
Shield Therapeutics
N/AGBX 4
-1.2%
N/A-51.9%£31.28M£21.47M-100.0040,000News Coverage

Related Companies and Tools


This page (LON:HIK) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners